LabCorpPatient ReportSpecimen ID:Acct #: 17452095Phone: (800) 539-6119Rte: 00

Control ID: Walk-In Lab, LLC 1645 Tiffany Lane

Mandeville LA 7044&- -- ---- --- --- ---

Patient Details
DOB:
Age(y/m/d):

Specimen Details
Date collected:
Date entered:

Physician Details
Ordering: W SMITH
Referring:

Age(y/m/d):Date entered:Referring:Gender:SSN:Date reported:ID: C34593Patient ID:NPI: 1326197864

**General Comments & Additional Information** 

Alternate Control Number:

Total Volume: Not Provided

Fasting: Yes

Alternate Patient ID: Not Provided

Fasting: Yes

**Ordered Items** 

Inflammatory Bowel Disease-IBD; Drawing Fee

illiaminatory beworbloodee ibb; brawing ree						
TESTS	RESULT	FLAG	UNITS	REFERENCE	INTERVAL	LAB
Inflammatory Bowel Disease-IB	D					
Saccharomyces cerevisiae, Igo	3					
	<20.0		Units		- 24.9 <20.0	01
			Negat		- 24.9	
			_		- 24.9 r= 25.0	
Coacharamraga agraviaina Ta	A		POSIC	ive >o	L= 25.U	
Saccharomyces cerevisiae, Ig						
	<20.0		Units		- 24.9	01
				tive		
				vocal 20.1		
					r= 25.0	
IgA and IgG antibody testing for S. cerevisiae is						
useful adjunct testing for differentiating Crohn's						
disease and ulcerative colitis. Close to 80% of						
Crohn's disease patients are positive for either						
IgA or IgG. In ulcerative colitis, less than 15% are						
positive for IgG and less than 2% are positive for						
IgA. Fewer than 5% are positive for either IgG or						
IgA antibody, and no healthy controls had antibody for both.						
Atypical pANCA	<1:20		titer	Neg:	<1:20	01
The atypical pANCA patte	rn has been	n observed	in a si	gnificant		
percentage of patients with ulcerative colitis, primary sclerosing						
cholangitis and autoimmu	ne hepatit	is.	_	_	_	
ASCA+/PANCA- Suggestive of Crohn's disease						
ASCA-/PANCA+ Suggestive of Ulcerative colitis						

01 BN LabCorp Burlington Dir: William F Hancock, MD 1447 York Court, Burlington, NC 27215-3361

For inquiries, the physician may contact Branch: 504-828-2666 Lab: 800-762-4344